Search Within

Paola Ghione

Formats
  1. Meeting Abstract (58)
  2. Journal Article (26)
  3. Editorial (3)
  4. Research Letter (3)
  5. Review (2)
Groups
  1. Sloan Kettering Institute Postdocs (92)
  2. Department of Medicine (78)
  3. Hematologic Malignancies, Division of (78)
  4. Center for Hematologic Malignancies (76)
  5. Lymphoma (75)
  6. Population Sciences Research Program (59)

More Groups

People
  1. Steven Horwitz (59)
  2. Alison Moskowitz (50)
  3. Maria Palomba (45)
  4. Ahmet Dogan (37)
  5. Ariela Noy (37)
  6. Andrew Zelenetz (35)

More People

Years
  1. 2025 (9)
  2. 2024 (29)
  3. 2023 (23)
  4. 2022 (2)
  5. 2021 (6)
  6. 2020 (14)

More Years

Publications
  1. Blood (45)
  2. Hematological Oncology (8)
  3. Journal of Clinical Oncology (6)
  4. Haematologica (5)
  5. Blood Advances (4)
  6. Leukemia and Lymphoma (3)

More Publications

Publishers
  1. American Society of Hematology (49)
  2. Wiley Blackwell (12)
  3. American Society of Clinical Oncology (6)
  4. Ferrata Storti Foundation (5)
  5. Taylor & Francis Group (4)
  6. Elsevier Inc. (3)

More Publishers

Results (92)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Ganesan, N.; Chang, T.; Davey, T.; Hancock, H.; Smith, M.; Assini, A.; Sarmasti, L.; Miller, T.; Gibaldi, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ferreira Lopes, A.; Hamlin, P. A.; Lue, J. K.; Ghione, P.; Owens, C.; Torka, P.; Kumar, A.; Steiner, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Characterization of skin response in patients with mycosis fungoides and sezary syndrome treated with mogamulizumab: A retrospective, real world cohort
    Meeting Abstract

    Christensen, R.; Stuver, R.; Dusza, S.; Epstein-Peterson, Z. D.; Ghione, P.; Horwitz, S.; Johnson, W. T.; Moskowitz, A.; Myskowski, P.; Pulitzer, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab for front-line treatment of extranodal NK/T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Advani, R. H.; Ganesan, N.; Chang, T.; Hancock, H.; Davey, T.; Miller, T.; Gibaldi, A.; Smith, M.; Assini, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Central nervous system bridging radiotherapy (CNS-BRT) achieves rapid cytoreduction prior to car T-cell therapy for aggressive B-cell lymphomas
    Meeting Abstract

    Cederquist, G.; Schefflein, J.; Devlin, S.; Shah, G.; Shouval, R.; Hubbeling, H.; Tringale, K.; Fregonese, B.; Hajj, C.; Boardman, A.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse
    Review

    Ghione, P.; Lewis, K. L.; Bobillo, S.; Nayak, L.; Schorb, E.; Nichelli, L.; Ng, A.; Savage, K. J.; McKay, P.; Nastoupil, L.; more...
    Hematological Oncology (2024)

    Fulltext@MSK | Save
  • Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
    Research Letter

    Lue, J. K.; Luttwak, E.; Rivas-Delgado, A.; Irawan, H.; Boardman, A.; Caron, P. C.; David, K.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas
    Journal Article

    Cederquist, G. Y.; Schefflein, J.; Devlin, S. M.; Shah, G. L.; Shouval, R.; Hubbeling, H.; Tringale, K.; Tomas, A. A.; Fregonese, B.; Hajj, C.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save